Nissim Darvish - Medigus Chairman of the Board
| MDGSDelisted Stock | USD 2.36 0.15 6.79% |
Chairman
Dr. Nissim Darvish serves as Chairman of the Board of Medigus Ltd. Dr. Darvish is a Senior Managing Director at OrbiMed. Dr. Davish is a veteran of the life science industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Dr. Darvish spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Dr. Darvish was the founder and CEO of Impulse Dynamics, which he led for six years
| Professional Marks | Ph.D |
| Phone | 972 73 370 4691 |
| Web | https://www.medigus.com |
Medigus Management Efficiency
The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| Kelvyn Cullimore | Dynatronics | 61 | |
| Roger Stoll | Delcath Systems | 73 | |
| Laing Rikkers | ProSomnus Common Stock | N/A | |
| Richard Ferrari | Tenon Medical | 70 | |
| Jeffrey Sr | STRATA Skin Sciences | 56 | |
| Jeffrey ODonnell | STRATA Skin Sciences | 57 | |
| Michael Degen | Nortech Systems Incorporated | 70 | |
| Dan Gladney | ReShape Lifesciences | 71 | |
| David Zacut | BrainsWay | 62 | |
| Will Moore | IRIDEX | 65 | |
| William Moore | IRIDEX | 68 | |
Management Performance
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0663 |
Medigus Ltd ADR Leadership Team
Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ilan Oren, Executive Officer | ||
| Efrat Venkert, External Director | ||
| Anat Naschitz, Director | ||
| Yaron Silberman, Chief Ltd | ||
| Ori Hershkovitz, External Director | ||
| Yair Rabinovitch, Director | ||
| Menashe Sonnenschein, Vice President - Operations | ||
| Gilad Mamlok, CFO | ||
| Christopher Rowland, CEO and Director | ||
| Eitan Machover, Independent Director | ||
| Minelu Sonnenschein, VP of Operations | ||
| Oded Yatzkan, Director of Fin. and Accounting and VP | ||
| Nissim Darvish, Chairman of the Board | ||
| Jeremy Starkweather, Director of Sales, Director of Marketing-United States | ||
| Yuval Yanai, Director | ||
| Aviel Shapira, Medical Director | ||
| Yair Rabinowitch, Director | ||
| Liron Carmel, Chief Officer | ||
| Erez Haimovitz, Director | ||
| Tali Dinar, Chief Officer | ||
| Doron Birger, Director | ||
| Tatyana Yossef, Controller | ||
| Yaron Zilberman, Vice President - Sales and Marketing |
Medigus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0663 | |||
| Profit Margin | (0.13) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 65.3 M | |||
| Shares Outstanding | 1.89 M | |||
| Shares Owned By Institutions | 0.29 % | |||
| Number Of Shares Shorted | 4.18 K | |||
| Price To Earning | 33.86 X | |||
| Price To Book | 0.15 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medigus in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medigus' short interest history, or implied volatility extrapolated from Medigus options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Medigus Stock
If you are still planning to invest in Medigus Ltd ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigus' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |